5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong third-quarter results, beating estimates for earnings and sales. J&J consequently raised its total revenue expectation for the year as it expects an improved performance in the rest of the year. However, the company lowered its adjusted earnings expectation due to the recent acquisition costs incurred.Per the Zacks classification, the pharma/biotech industry comes under the broader Medi ...